Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and best dose of propranolol when administered
concurrently with SOC neoadjuvant CRT in patients with esophageal carcinoma, with a safety
lead-in and dose expansion cohort. Patients who are already on β-blockers will receive
standard of care CRT and will be considered separately as a single arm prospective cohort